文献速递自身免疫性与大疱性皮肤病药疹与重症皮肤不良反应皮肤肿瘤

癌症患者大疱性类天疱疮与免疫检查点抑制剂治疗的关联:一项系统综述

Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
PubMed 文献 · JAMA Dermatol · 2022-01-01

该系统综述纳入70项研究、127例接受免疫检查点抑制剂治疗的癌症患者,描述免疫检查点抑制剂诱发的大疱性类天疱疮(ICI-BP)的危险因素、临床表现、诊断、治疗及结局。ICI-BP多发生于抗PD-1、PD-L1或CTLA-4治疗期间,也可在停药后数月出现,约半数患者有前驱症状,多数患者停用免疫治疗并接受糖皮质激素治疗,生物制剂对难治病例可带来明显症状改善。

要点

  • ICI-BP可发生于抗PD-1、PD-L1或CTLA-4治疗期间,也可在停药后数月出现。
  • 约半数患者出现瘙痒或非特异性皮疹等前驱症状。
  • 多数患者停用免疫治疗,最常见治疗为全身和局部糖皮质激素。

核心结论

  • 该系统综述结果提示,ICI-BP常给接受免疫治疗的癌症患者带来治疗挑战。
  • 进一步研究早期识别、诊断和靶向治疗模式的应用,对于制定更个性化的治疗方案、同时减少发病率和死亡率至关重要。

研究设计与样本

  • 系统综述,检索PubMed、Embase、Web of Science和Cochrane系统综述数据库,遵循PRISMA报告指南。
  • 纳入报告个体患者数据的文章,患者需符合预设纳入标准,并提取预设数据集。
  • 共纳入70项研究、127例因癌症接受免疫检查点抑制剂治疗的个体患者,中位(IQR)年龄71(64-77)岁,女性27例(21.3%)。
  • 在汇总分析中,患者年龄范围为35至90岁。
  • 在可能的情况下,对研究结果进行定量合并。

主要发现

  • ICI-BP常发生于抗PD-1、PD-L1或细胞毒性T淋巴细胞相关抗原4治疗期间,但也发现可在治疗停止后长达数月出现。
  • 约半数患者出现前驱症状,如瘙痒或非特异性皮疹。
  • 进行组织病理学或血清学检测时,有助于辅助确立诊断。
  • 大多数患者在发生ICI-BP后停用免疫治疗。
  • 最常见的治疗为全身和局部糖皮质激素;保类固醇治疗(如抗生素和其他全身免疫调节剂)也用作辅助治疗;生物制剂和靶向药物主要用于对糖皮质激素治疗难治的病例,与大多数患者症状明显改善相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is limited information on immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) in patients with cancer, with most existing studies being case reports or small case series from a single institution. Prior review attempts have not approached the literature in a systematic manner and have focused only on ICI-BP secondary to anti-programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) therapy. The current knowledge base of all aspects of ICI-BP is limited. OBJECTIVE: To characterize the risk factors, clinical presentation, diagnostic findings, treatments, and outcomes of ICI-BP in patients with cancer as reported in the current literature. EVIDENCE REVIEW: A systematic review was performed using PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. Articles reporting data on individual patients who met preestablished inclusion criteria were selected, and a predefined set of data was abstracted. When possible, study results were quantitatively combined. FINDINGS: In total, 70 studies reporting data on 127 individual patients undergoing ICI therapy for cancer (median [IQR] age, 71 [64-77] years; 27 women [21.3%]) were included. In pooled analyses, patients ranged in age from 35 to 90 years. Immune checkpoint inhibitor-induced bullous pemphigoid often occurred during the course of anti-PD-1, PD-L1, or cytotoxic T lymphocyte-associated antigen 4 therapy but was also found to develop up to several months after treatment cessation. Prodromal symptoms, such as pruritus or nonspecific skin eruptions, were found in approximately half of the patient population. Histopathologic or serologic testing, when undertaken, was a helpful adjunct in establishing diagnosis. Treatment with immunotherapy was discontinued after ICI-BP development in most patients. The most common treatments were systemic and topical corticosteroids. Steroid-sparing therapies, such as antibiotics and other systemic immunomodulators, were also used as adjuvant treatment modalities. Biologic and targeted agents, used predominantly in cases refractory to treatment with corticosteroids, were associated with marked symptomatic improvement in most patients. CONCLUSIONS AND RELEVANCE: The results of this systematic review suggest that ICI-BP often poses a therapeutic challenge for patients with cancer who are receiving immunotherapy. Further research on the early recognition, diagnosis, and use of targeted treatment modalities will be essential in developing more personalized treatment options for affected patients while minimizing morbidity and mortality.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Asdourian MS, Shah N, Jacoby TV, et al. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review. JAMA Dermatol. 2022. PMID: 35612829. doi:10.1001/jamadermatol.2022.1624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。